var data={"title":"Cyanocobalamin (vitamin B12): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cyanocobalamin (vitamin B12): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5954?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cyanocobalamin-vitamin-b12-drug-information\" class=\"drug drug_general\">see &quot;Cyanocobalamin (vitamin B12): Drug information&quot;</a> and <a href=\"topic.htm?path=cyanocobalamin-vitamin-b12-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cyanocobalamin (vitamin B12): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155136\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>B-12 Compliance Injection;</li>\n      <li>Nascobal;</li>\n      <li>Physicians EZ Use B-12;</li>\n      <li>Vitamin Deficiency System-B12</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057483\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Nutritional Supplement</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vitamin, Water Soluble</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442273\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adequate intake (AI):</b> Oral: 0.4 mcg/day (~0.05 mcg/kg/day) (IOM 1998); <b>Note:</b> Neonates born to vegan mothers should be supplemented with the AI for vitamin B12 from birth; they may have low vitamin B12 stores at birth and, if breastfeeding, may only receive a small amount of the vitamin from the mother's milk (Mangels 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anemia of prematurity:</b> Limited data available: IM: 100 mcg once monthly for 4 months with concomitant folic acid administration produced higher hemoglobin in 34 preterm neonates (GA &lt;36 weeks; birth weight &lt;1,800 g) when compared to placebo or folate monotherapy; all patients received vitamin E and iron supplementation (Worthington-White 1994).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pernicious anemia; treatment of deficiency:</b> Limited data available: IM, SubQ: Initial: 1,000 mcg/day for 2 to 7 days based upon clinical response; followed by 100 mcg once weekly for 4 weeks and then maintenance dose: 100 mcg/month; <b>Note:</b> For severe anemia, a lower initial dose of 0.2 mcg/kg/dose for 2 days followed by the above regimen has been recommended due to potential hypokalemia observed during initial treatment of adults with severe anemia (Orkin 2015; Rasmussen 2001); however, in more recent experience, while some adult patients may experience hypokalemia with initial treatment, this is unlikely to be clinically significant (Carmel 2008). Some experts have recommended doses as low as 50 to 100 mcg (Orkin 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057477\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cyanocobalamin-vitamin-b12-drug-information\" class=\"drug drug_general\">see &quot;Cyanocobalamin (vitamin B12): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Adequate intake (AI) (IOM 1998):</b> Oral: <b>Note:</b> Neonates born to vegan mothers should be supplemented with the AI for vitamin B12 from birth; they may have low vitamin B12 stores at birth and, if breastfeeding, may only receive a small amount of the vitamin from the mother's milk (Mangels 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 1 to 6 months: 0.4 mcg/day (0.05 mcg/kg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 7 to 12 months: 0.5 mcg/day (0.05 mcg/kg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommended daily allowance (RDA) (IOM 1998):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">1 to 3 years: 0.9 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">4 to 8 years: 1.2 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">9 to 13 years: 1.8 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;14 years: 2.4 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pernicious anemia:</b> <b>Note: </b>Concurrent folic acid supplementation may also be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling: </i>Infants, Children, and Adolescents: IM, SubQ: 100 mcg once daily for 6 to 7 days; if improvement occurs, administer 100 mcg on alternate days for 7 doses, then every 3 to 4 days for 2 to 3 weeks; once hematologic values have returned to normal, maintenance dose: 100 mcg monthly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate dosing</i>: Limited data available: Infants, Children, and Adolescents: IM, SubQ: Initial: 1,000 mcg/day for 2 to 7 days based upon clinical response; followed by 100 mcg once weekly for 4 weeks and then maintenance dose: 100 mcg/month; for severe anemia, a lower initial dose of 0.2 mcg/kg/dose for 2 days followed by the above regimen has been recommended due to potential hypokalemia observed during initial treatment of adults with severe anemia (Orkin 2015; Rasmussen 2001; Stabler 2013); however, in more recent experience, while some adult patients may experience hypokalemia with initial treatment, this is unlikely to be clinically significant (Carmel 2008). For infants and young children, some experts have recommended doses as low as 50 to 100 mcg (Orkin 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin B12 deficiency, severe:</b> Limited data available; dosing regimens variable:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dietary deficiency: </i>Infants (breastfed with vitamin B12 deficient mothers): IM: 250 to 1,000 mcg once daily for 1 to 2 weeks, followed by weekly dosing until patient recovers (Stabler 2013); patients with neurologic symptoms have been treated with doses of 1,000 mcg (Guez 2012; Roumeliotis 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Malabsorption: </i>Infants, Children, and Adolescents: IM: 250 to 1,000 mcg daily or every other day for 1 week, then weekly for 4 to 8 weeks, and then monthly for life; younger children should receive monthly doses of 100 mcg (Bj&oslash;rke-Monsen 2011; Kliegman 2016; Stabler 2013). For infants and young children, some experts have recommended doses as low as 50 to 100 mcg (Orkin 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommended intake (IOM 1998):</b> 2.4 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pregnancy: 2.6 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lactation: 2.8 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin B12 deficiency: Note:</b> Folic acid supplementation may also be required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal (Nascobal): 500 mcg (1 spray) in one nostril once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 1,000 to 2,000 mcg daily for 1 to 2 weeks; maintenance: 1,000 mcg daily (Langan 2011; Oh 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, deep SubQ: May use initial treatment similar to that for pernicious anemia depending on severity of deficiency: 100 mcg daily for 6 to 7 days; if improvement, administer same dose on alternate days for 7 doses, then every 3 to 4 days for 2 to 3 weeks; once hematologic values have returned to normal, maintenance dosage: 100 mcg monthly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Higher doses may be preferred, especially in cases of severe deficiency; consider alternate dosing regimens with initial doses ranging from 100 to 1,000 mcg every day or every other day for 1 to 2 weeks and maintenance doses of 100 to 1,000 mcg every 1 to 3 months (Oh 2003) <b>or</b> 1,000 mcg once a week for 8 weeks followed by 1,000 mcg once a month (Langan 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Pernicious anemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM: 1,000 mcg once daily or every other day for 1 week, then 1,000 mcg weekly for 4 to 8 weeks, then 1,000 mcg once monthly for life (Stabler 2013) <b>or</b> 100 to 1,000 mcg every day or every other day for 1 to 2 weeks followed by 100 to 1,000 mcg every 1 to 3 months (Oh 2003) <b>or</b> 1,000 mcg once a week for 8 weeks followed by 1,000 mcg once a month for life (Langan 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 1,000 to 2,000 mcg once daily for life (Stabler 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM, deep SubQ (administer concomitantly with folic acid if needed): 100 mcg daily for 6 to 7 days; if improvement, administer same dose on alternate days for 7 doses; then every 3 to 4 days for 2 to 3 weeks; once hematologic values have returned to normal, maintenance dosage: 100 mcg monthly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. Some formulations may also contain aluminum, which may accumulate in renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155113\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">B-12 Compliance Injection: 1000 mcg/mL [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Physicians EZ Use B-12: 1000 mcg/mL [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vitamin Deficiency System-B12: 1000 mcg/mL [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1000 mcg/mL [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Sublingual: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 3000 mcg/mL (52 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Lozenge, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mcg (100 ea); 100 mcg (100 ea); 250 mcg (100 ea, 250 ea); 500 mcg (100 ea, 250 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1000 mcg/mL (1 mL, 10 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Nasal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nascobal: 500 mcg/0.1 mL (1 ea, 1.3 mL [DSC]) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mcg, 250 mcg, 500 mcg, 1000 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mcg, 500 mcg, 1000 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1000 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Sublingual, Sublingual: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2500 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Sublingual, Sublingual [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2500 mcg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155098\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057487\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal: Nascobal nasal spray: Prior to initial dose, activate (prime) spray nozzle by pumping unit quickly and firmly until first appearance of spray, then prime twice more. The unit must be reprimed once immediately before each use. Administer at least one hour before or after ingestion of hot foods or liquids; hot foods can cause nasal secretions and a resulting loss of medication</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Not generally recommended for treatment of severe vitamin B12 deficiency due to poor oral absorption (lack of intrinsic factor); oral administration may be used in less severe deficiencies and maintenance therapy; may be administered without regard to food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: IM or deep SubQ are preferred routes of administration: Avoid IV administration due to a more rapid system elimination with resulting decreased utilization</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual: Place under the tongue and allow to dissolve; do not swallow whole, chew, or crush</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155131\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Clear pink to red solutions are stable at room temperature. Protect from light. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal spray: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze. Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057486\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of pernicious anemia; vitamin B12 deficiency due to dietary deficiencies or malabsorption diseases; inadequate secretion of intrinsic factor, inadequate utilization of B12 (eg, during neoplastic treatment); increased B12 requirements due to pregnancy, thyrotoxicosis, hemorrhage, malignancy, liver or kidney disease (FDA approved in pediatric patients [age not specified] and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155185\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac failure, peripheral vascular disease, thrombosis (peripheral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal gait, anxiety, ataxia, dizziness, headache, hypoesthesia, nervousness, pain, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash (transient), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, dyspepsia, glossitis, nausea, sore throat, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; Oncologic: Polycythemia vera</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis (parenteral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthritis, back pain, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, pulmonary edema, rhinitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155120\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cyanocobalamin (vitamin B<sub>12</sub>), cobalt, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155102\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Vitamin B<sub>12</sub> deficiency for &gt;3 months results in irreversible degenerative CNS lesions; neurologic manifestations will not be prevented with folic acid unless vitamin B<sub>12</sub> is also given. Spinal cord degeneration might also occur when folic acid used as a substitute for vitamin B<sub>12</sub> in anemia prevention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: According to the manufacturer, treatment of severe vitamin B<sub>12</sub> megaloblastic anemia may result in severe hypokalemia, sometimes fatal, due to intracellular potassium shift upon anemia resolution; however, in more recent experience, while some patients may experience hypokalemia with initial treatment, this is unlikely to be clinically significant (Carmel 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombocytosis: Treatment of severe vitamin B<sub>12</sub> megaloblastic anemia may result in thrombocytosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Leber disease: Patients with Leber disease who received B<sub>12</sub> treatment have suffered from severe rapid optic atrophy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pernicious anemia: Appropriate use: IM/SubQ routes are used to treat pernicious anemia; oral and intranasal administration are not indicated until hematologic remission and no signs of nervous system involvement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polycythemia vera: Vitamin B<sub>12</sub> deficiency masks signs of polycythemia vera; vitamin B<sub>12</sub> administration may unmask this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intranasal administration: Efficacy in patients with nasal pathology or with other concomitant intranasal therapy has not been determined. Use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IV administration: Avoid intravenous route; anaphylactic shock has occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Test dose: Intradermal test dose of vitamin B<sub>12</sub> is recommended for any patient suspected of cyanocobalamin sensitivity prior to intranasal or injectable administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299104\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155106\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13187&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): May diminish the therapeutic effect of Vitamin B12.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: May decrease the serum concentration of Cyanocobalamin.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155133\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Heavy ethanol consumption &gt;2 weeks may impair vitamin B<sub>12</sub> absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14207663\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Water soluble vitamins cross the placenta. Absorption of vitamin B<sub>12</sub> may increase during pregnancy. Vitamin B<sub>12</sub> requirements may be increased in pregnant women compared to nonpregnant women. Serum concentrations of vitamin B<sub>12</sub> are higher in the neonate at birth than the mother (IOM, 1998).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057482\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vitamin B12, hemoglobin, hematocrit, erythrocyte and reticulocyte count, folate and iron levels should be obtained prior to treatment; vitamin B12 and peripheral blood counts should be monitored 1 month after beginning treatment, then every 3 to 6 months thereafter.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Evaluate serum methylmalonic acid (MMA) and total homocysteine levels at baseline (prior to supplementation) in untreated patients to confirm vitamin B12 deficiency (and extent of deficiency); repeat to confirm adequate supplementation (Stabler 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Megaloblastic/pernicious anemia: In addition to normal hematological parameters, serum potassium and platelet counts should be monitored during therapy. <b>Note:</b> Some patients may develop hypokalemia during initial treatment; however, this is unlikely to be clinically significant (Carmel 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057485\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Serum vitamin B12 levels: Normal: &gt;300 pg/mL; vitamin B12 deficiency: &lt;200 pg/mL (200 to 300 pg/mL borderline result, possible deficiency); megaloblastic anemia: &lt;100 pg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155101\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Coenzyme for various metabolic functions, including fat and carbohydrate metabolism and protein synthesis, used in cell replication and hematopoiesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155119\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Megaloblastic anemia: IM: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Conversion of megaloblastic to normoblastic erythroid hyperplasia within bone marrow: 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Increased reticulocytes: 2 to 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Complicated vitamin B<sub>12</sub> deficiency: IM, SubQ: Resolution of: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Psychiatric sequelae: 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Thrombocytopenia: 10 days </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Granulocytopenia: 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Variable from the terminal ileum; requires the presence of calcium and gastric &ldquo;intrinsic factor&rdquo; to transfer the compound across the intestinal mucosa </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Principally stored in the liver and bone marrow, also stored in the kidneys and adrenals </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Transcobalamins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Converted in tissues to active coenzymes, methylcobalamin and deoxyadenosylcobalamin; undergoes some enterohepatic recycling </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Intranasal solution: Intranasal gel: 8.9% (relative to IM formulation); Nascobal: 6.1% (relative to IM); Oral: Pernicious anemia: 1.2% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM, SubQ: 30 minutes to 2 hours; Intranasal: 1.6 hours  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (50% to 98%, unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155122\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cyanocobalamin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mcg/mL (10 mL): $51.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nascobal Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg/0.1 mL (1): $158.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Vitamin B-12 ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mcg (60): $3.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Vitamin B-12 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg (100): $3.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mcg (100): $5.02</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155124\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ambe 12 (LU);</li>\n      <li>Ampavit (TH);</li>\n      <li>Arcored (ID);</li>\n      <li>B12 Ankermann (PL);</li>\n      <li>Bedoc (GR);</li>\n      <li>Bedodeka (IL);</li>\n      <li>Bedoze (PT);</li>\n      <li>Bedozil (BR);</li>\n      <li>Behepan (SE);</li>\n      <li>Betolvex (CH, DK, FI, SE);</li>\n      <li>Betolvex[inj.] (SE);</li>\n      <li>Cianocobalamina B12 Davi (PT);</li>\n      <li>Coba 1000 (LK);</li>\n      <li>Cobalin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Cobamin Ophth Soln (HK);</li>\n      <li>Creliverol-12 (PE);</li>\n      <li>Cromatonbic B12 (ES);</li>\n      <li>Cytacon (LK);</li>\n      <li>Cytamen (AU, GB);</li>\n      <li>Dobetin (IT, VE);</li>\n      <li>Dodec (TR);</li>\n      <li>Ecovitamine B12 (FR);</li>\n      <li>Isopto B12 (ES);</li>\n      <li>Kiddi Pharmaton (MX);</li>\n      <li>Lagavit B12 (AE, BB, BH, BM, BS, BZ, CY, EG, GY, IQ, IR, JM, JO, KW, LB, LY, NL, OM, PR, QA, SA, SR, SY, TT, YE);</li>\n      <li>Ledoxina (MX);</li>\n      <li>Mono Vitamine B12 (FR);</li>\n      <li>Neurobene (CZ, HN);</li>\n      <li>Norivite-12 (ZA);</li>\n      <li>Optovite B12 (ES);</li>\n      <li>Parecon Forte (ZW);</li>\n      <li>Permadoze (PT);</li>\n      <li>Permadoze oral (PT);</li>\n      <li>Reedvit 10000 (AR);</li>\n      <li>Reticulogen (ES);</li>\n      <li>Rojamin (EC);</li>\n      <li>Rubramin (PH);</li>\n      <li>Sancoba (JP);</li>\n      <li>Tribedoce DX (MX);</li>\n      <li>Vegevit B12 (PL);</li>\n      <li>Vicapan N (DE);</li>\n      <li>Vitalen (MX);</li>\n      <li>Vitam-Doce (AR);</li>\n      <li>Vitamin B!1!2 (HR);</li>\n      <li>Vitamin B12 (HU);</li>\n      <li>Vitamin B12 Lannacher (AT);</li>\n      <li>Vitamin B12 Recip (SE);</li>\n      <li>Vitamina B12-Ecar (CO);</li>\n      <li>Vitamine B12-Dulcis (LU);</li>\n      <li>Vitaminum B12 (PL);</li>\n      <li>Vitarubin (CH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyanocobalamin-vitamin-b12-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyanocobalamin-vitamin-b12-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bj&oslash;rke-Monsen AL, Ueland PM. Cobalamin status in children. <i>J Inherit Metab Dis</i>. 2011;34(1):111-119.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyanocobalamin-vitamin-b12-pediatric-drug-information/abstract-text/20508991/pubmed\" target=\"_blank\" id=\"20508991\">20508991</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carmel R. How I treat cobalamin (vitamin B12) deficiency. <i>Blood</i>. 2008;112(6):2214-2221.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyanocobalamin-vitamin-b12-pediatric-drug-information/abstract-text/18606874/pubmed\" target=\"_blank\" id=\"18606874\">18606874</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyanocobalamin-vitamin-b12-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cyanocobalamin injection [prescribing information]. Mendham, NJ: Somserset Therapeutics, LLC; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Department Health and Human Services, Food Drug Administration. Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Federal Register</i>. 2000;65(17):4103-4111.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guez S, Chiarelli G, Menni F, Salera S, Principi N, Esposito S. Severe vitamin B12 deficiency in an exclusively breastfed 5-month-old Italian infant born to a mother receiving multivitamin supplementation during pregnancy. <i>BMC Pediatr</i>. 2012;12:85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyanocobalamin-vitamin-b12-pediatric-drug-information/abstract-text/22726312/pubmed\" target=\"_blank\" id=\"22726312\">22726312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute of Medicine (IOM). <i>Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin and Choline</i>. Washington, DC: National Academy Press; 1998.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lane LA and Rojas-Fernandez C, &ldquo;Treatment of Vitamin B(12)-Deficiency Anemia: Oral Versus Parenteral Therapy,&rdquo; <i>Ann Pharmacother</i>, 2002, 36(7):1268-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyanocobalamin-vitamin-b12-pediatric-drug-information/abstract-text/12086562/pubmed\" target=\"_blank\" id=\"12086562\">12086562</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Langan RC, Zawistoski KJ. Update on vitamin B12 deficiency.<i> Am Fam Physician</i>. 2011;83(12):1425-1430.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyanocobalamin-vitamin-b12-pediatric-drug-information/abstract-text/21671542 /pubmed\" target=\"_blank\" id=\"21671542 \">21671542 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mangels AR and Messina V, &quot;Considerations in Planning Vegan Diets: Infants,&quot; <i>J Am Diet Assoc</i>, 2001, 101(6):670-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyanocobalamin-vitamin-b12-pediatric-drug-information/abstract-text/11424546/pubmed\" target=\"_blank\" id=\"11424546\">11424546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orkin S, Nathan D, Ginsbirg, D, et al, eds. <i>Nathan and Oski's Hematology and Oncology of Infancy and Childhood</i>. 8th ed. Saunders; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oh R, Brown DL. Vitamin B12 deficiency. <i>Am Fam Physician</i>. 2003;67(5):979-986.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyanocobalamin-vitamin-b12-pediatric-drug-information/abstract-text/12643357 /pubmed\" target=\"_blank\" id=\"12643357 \">12643357 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rasmussen SA, Fernhoff PM, and Scanlon KS, &ldquo;Vitamin B<sub>12</sub> Deficiency in Children and Adolescents,&rdquo; <i>J Pediatr</i>, 2001, 138(1):10-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyanocobalamin-vitamin-b12-pediatric-drug-information/abstract-text/11148506/pubmed\" target=\"_blank\" id=\"11148506\">11148506</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roumeliotis N, Dix D, Lipson A. Vitamin B(12) deficiency in infants secondary to maternal causes. <i>CMAJ</i>. 2012;184(14):1593-1598.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyanocobalamin-vitamin-b12-pediatric-drug-information/abstract-text/22711730/pubmed\" target=\"_blank\" id=\"22711730\">22711730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stabler SP. Clinical practice. Vitamin B12 deficiency. <i>N Engl J Med</i>. 2013;368(2):149-160.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyanocobalamin-vitamin-b12-pediatric-drug-information/abstract-text/23301732/pubmed\" target=\"_blank\" id=\"23301732\">23301732</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Worthington-White DA, Behnke M, and Gross S, &quot;Premature Infants Require Additional Folate and Vitamin B<sub>12</sub> to Reduce the Severity of the Anemia of Prematurity,&quot; <i>Am J Clin Nutr</i>, 1994, 60(6):930-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyanocobalamin-vitamin-b12-pediatric-drug-information/abstract-text/7985636/pubmed\" target=\"_blank\" id=\"7985636\">7985636</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13187 Version 156.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F155136\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1057483\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442273\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1057477\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F155113\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F155098\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1057487\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F155131\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1057486\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F155185\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F155120\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F155102\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299104\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F155106\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F155133\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14207663\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1057482\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1057485\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F155101\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F155119\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F155122\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F155124\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13187|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cyanocobalamin-vitamin-b12-drug-information\" class=\"drug drug_general\">Cyanocobalamin (vitamin B12): Drug information</a></li><li><a href=\"topic.htm?path=cyanocobalamin-vitamin-b12-patient-drug-information\" class=\"drug drug_patient\">Cyanocobalamin (vitamin B12): Patient drug information</a></li></ul></div></div>","javascript":null}